Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma

Lilly Wilson, Adam D. Cohen, MD, Brendan M. Weiss, MD, Dan T. Vogl, MD, Alfred L. Garfall, MD, Donna L. Capozzi, PharmD, Patricia Mangan, MSN, CRNP, Mary Sanchez, MSN, CRNP, Colleen Erb, MSN, CRNP, Edward Stadtmauer, MD

Blood (2016) 128 (22): 2119.

https://doi.org/10.1182/blood.V128.22.2119.2119

Published: 2016

Journal Articles

Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance

Jennifer McQuade, MD, Tahamtan Ahmadi, MD, PhD, David Porter, Noelle Frey, Alison Wakoff Loren, MD, MS, Steven C. Goldstein, MD, Jakub Svoboda, MD, Edward Stadtmauer, MD, Stephen J. Schuster, MD, Sunita Dwivedy Nasta, MD

Blood (2010) 116 (21): 3570.

https://doi.org/10.1182/blood.V116.21.3570.3570

Published: 2010

Journal Articles

Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil*®) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts: Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization.

Ivana N Micallef, MD, Patrick Stiff, MD, Edward Stadtmauer, MD, Brian J. Bolwell, Sachin Marulkar, MBBS, MPH, Frank J Hsu, MD, John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 2319.

https://doi.org/10.1182/blood.V114.22.2319.2319

Published: 2009

Journal Articles

Mobilization with Plerixafor (Mozobil ® )Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.

Brian J. Bolwell, Auayporn P. Nademanee, MD, Patrick Stiff, MD, Edward Stadtmauer, MD, Richard T. Maziarz, MD, Ivana N Micallef, MD, Sachin Marulkar, MBBS, MPH, Pritesh Gandhi, PharmD, John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 3224.

https://doi.org/10.1182/blood.V114.22.3224.3224

Published: 2009

Journal Articles

Plerixafor (Mozobi ® )Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (<20 cells/μl) Peripheral Blood CD34+ Cell Count.

Auayporn P. Nademanee, MD, Edward Stadtmauer, MD, Ivana N Micallef, MD, Patrick Stiff, MD, Sachin Marulkar, MBBS, MPH, Gary C Calandra, M.D., Ph.D., John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 3230.

https://doi.org/10.1182/blood.V114.22.3230.3230

Published: 2009

Journal Articles

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

Steven C Goldstein, MD, Bruce Levine, PhD, Jacqueline Smith, MSN, CRNP, Joanne Hinkle, RN, BSN, OCN, Selina Luger, MD, Alexander Perl, MD, Alison Loren, MD, Noelle Frey, MD, Edward Stadtmauer, MD, Daniel Schullery, PhD, Jean Boyer, PhD, Dennis L. Confer, MD, David Porter, MD, Carl H. June, MD

Blood (2008) 112 (11): 468.

https://doi.org/10.1182/blood.V112.11.468.468

Published: 2008

Journal Articles

A Prospective Clinical Trial of a Novel Epstein-Barr Virus (EBV) PCR Panel in Patients with EBV Associated Malignancies.

Marin F. Xavier, MD, Dale Frank, MD, Sunita Nasta, MD, Stephen Schuster, MD, Charalambos Andreadis, MD, Sharon Arnoldi, Eric Sherman, MD, Sigrid Berg, MD, Anthony Mato, MD, Benjamin Musher, MD, Lisa Downs, David Porter, MD, Edward Stadtmauer, MD, Steven Goldstein, MD, Ellen Kim, MD, Donald Tsai, MD

Blood (2007) 110 (11): 2628.

https://doi.org/10.1182/blood.V110.11.2628.2628

Published: 2007

Journal Articles

Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.

Edward Stadtmauer, MD, Donna Weber, MD, M. Dimopolous, MD, Andrew Belch, MD, Michel Attal, MD, Miles Prince, MD, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, MD, Robert Knight, MD

Blood (2006) 108 (11): 3552.

https://doi.org/10.1182/blood.V108.11.3552.3552

Published: 2006

Journal Articles

Non-Myeloablative Conditioning with Allogeneic Progenitor Cell Transplantation for Relapsed Hodgkin’s Lymphoma: High Response Rate Despite Prior Chemoresistance.

Steven C. Goldstein, MD, Selina M. Luger, MD, Edward Stadtmauer, MD, Stephen Schuster, MD, Donald Tsai, MD, PhD, Sunita Nasta, MD, Alison Loren, MD, Alexander Perl, MD, Greg Orloff, MD, Julie Oliver, CRNP, Robert Sachs, Stephen Emerson, MD, PhD, David L. Porter, MD.

Blood (2004) 104 (11): 2258.

https://doi.org/10.1182/blood.V104.11.2258.2258

Published: 2004

Journal Articles

Utility of Prophylactic Autologous Stem Cell Collection for Patients with Acute Myeloid Leukemia in First Remission.

Margie Kasner, MD, Selina Luger, MD, Edward Stadtmauer, MD, Stephen Schuster, MD, Donald Tsai, MD, Sunita Nasta, MD, Alexander Perl, MD, Alison Loren, MD, Steven Goldstein, MD, Patricia Mangan, CRNP, Robert Sachs, Donald Seigel, MD, David Porter, MD

Blood (2004) 104 (11): 1872.

https://doi.org/10.1182/blood.V104.11.1872.1872

Published: 2004

Journal Articles

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Mats Brune, MD, Sylvie Castaigne, MD, John Catalano, MD, Kurt Gehlsen, PhD, Wolf-Karsten Hofmann, MD, Anthony Ho, MD, Donna Hogge, MD, Bo Nilsson, MD, Reuven Or, MD, Jacob Rowe, MD, Bengt Simonsson, MD, Ruth Spearing, MD, Edward Stadtmauer, MD, Jeff Szer, MD, Elisabeth Wallhult, RN, Kristoffer Hellstrand, MD

Blood (2004) 104 (11): 261.

https://doi.org/10.1182/blood.V104.11.261.261

Published: 2004

Journal Articles

A Predictive Model for Tumor Lysis Syndrome in Acute Myelogenous Leukemia.

Anthony R. Mato, MD, Brett E. Riccio, MD, Li Qin, PhD, Daniel Heitjan, PhD, Alison Loren, MD, Martin Carroll, MD, David Porter, MD, Donald Tsai, MD, Edward Stadtmauer, MD, Sasha Perl, MD, Alan Gewirtz, MD, Sunita Nasta, MD, Stephen Schuster, MD, Steven Goldstein, MD, Selina M. Luger, MD

Blood (2004) 104 (11): 883.

https://doi.org/10.1182/blood.V104.11.883.883

Published: 2004

Journal Articles

Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation.

David Porter, MD, Bruce Levine, PhD, Nancy Bunin, MD, Edward Stadtmauer, MD, Selina Luger, MD, Steven Goldstein, MD, Stephen Schuster, MD, Donald Tsai, MD, Sunita Nasta, MD, Alison Loren, MD, Alexander Perl, MD, Julie Oliver, CRNP, Ambika Sohal, Liz Veloso, RN, Stephen Emerson, MD, PhD, Carl June, MD

Blood (2004) 104 (11): 1640.

https://doi.org/10.1182/blood.V104.11.1640.1640

Published: 2004

NARROW

Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma

Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance

Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil*®) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts: Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization.

Mobilization with Plerixafor (Mozobil ® )Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.

Plerixafor (Mozobi ® )Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (<20 cells/μl) Peripheral Blood CD34+ Cell Count.

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

A Prospective Clinical Trial of a Novel Epstein-Barr Virus (EBV) PCR Panel in Patients with EBV Associated Malignancies.

Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.

Non-Myeloablative Conditioning with Allogeneic Progenitor Cell Transplantation for Relapsed Hodgkin’s Lymphoma: High Response Rate Despite Prior Chemoresistance.

Utility of Prophylactic Autologous Stem Cell Collection for Patients with Acute Myeloid Leukemia in First Remission.

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

A Predictive Model for Tumor Lysis Syndrome in Acute Myelogenous Leukemia.

Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only